Kahr Medical: Secures $18M in Funding Round
- KAHR Medical Ltd., a Jerusalem, Israel-based biopharmaceutical company developing a novel drug platform based on bi-functional
- The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test as a single agent
- Then the round completion is subject to customary closing conditions and expected to occur early next month
- Proceeds will used for advancing the company’s immuno-oncology drug candidates including the clinical development of its lead product
- That hypothesis untested in humans, but Kahr now has the means to start validating the idea